Vantage Consulting Group Inc - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 211 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2021. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.

Quarter-by-quarter ownership
Vantage Consulting Group Inc ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q4 2021$11,864,000
+40.4%
226,6700.0%3.19%
+76.2%
Q3 2021$8,450,000
-8.7%
226,6700.0%1.81%
+12.4%
Q2 2021$9,252,000
+20.3%
226,6700.0%1.61%
+4.3%
Q1 2021$7,690,000
+6.7%
226,6700.0%1.54%
+163.0%
Q4 2020$7,208,000226,6700.59%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q4 2021
NameSharesValueWeighting ↓
Sarissa Capital Management LP 640,000$25,626,0006.33%
Redmile Group, LLC 1,322,592$52,957,0004.01%
SENZAR ASSET MANAGEMENT, LLC 556,224$22,271,209,0003.24%
RA Capital Management 314,349$12,587,0001.81%
WALL STREET ASSOCIATES 205,657$8,235,0001.58%
Parametrica Management Ltd 5,400$216,0001.36%
Rhenman & Partners Asset Management AB 165,000$6,607,0001.05%
EAM Investors, LLC 95,168$3,811,0000.60%
Rock Springs Capital Management LP 180,000$7,207,0000.58%
WASATCH ADVISORS LP 1,085,973$43,482,0000.58%
View complete list of INTRA CELLULAR THERAPIES INC shareholders